EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, ‘Real-world’, Multicenter Study

Calogera Butera, Marcello Esposito, Trinchillo Assunta iD, Morena Giovannelli, Anna Rivaroli, Mario Pata, Mathieu Beneteau, Massimo Filippi iD, Patrizia M Caglioni, Ubaldo Del Carro iD

NeuroRehabilitation · 2025

DOI: 10.1177/10538135251329322 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift NeuroRehabilitation, 2025. Verfasst von Calogera Butera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Multiple Sclerosis, Muscle Spasticity, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ipsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While there is strong evidence for botulinum toxin-A (BoNT-A) in post-stroke spasticity, there is a paucity of data in multiple sclerosis and other conditions in real-world settings.

Objective

Document the use of BoNT-A in the management of spasticity, with focus on the treatment of spasticity due to stroke and multiple sclerosis.

Methods

This noninterventional, retrospective study included all adults treated for upper and/or lower limb spasticity (any etiology) at three centers in Italy who received ≥3 BoNT-A injection cycles between 2008 and 2018.

Results

Injection data from 149 patients were analyzed (n = 67 post-stroke, n = 47 MS, n = 35 other etiologies). The median treatment duration was 54.9 months in the post-stroke population and 41.9 months in the MS population. Total doses for the commercially available BoNT-A formulations were typically lower than approved for use in spasticity; we also observed clinically relevant differences in the muscle patterns treated between the MS and post-stroke indications. Regardless of etiology, most patients were satisfied with treatment.

Conclusions

This retrospective study provides a snapshot of spasticity management for patients referred for BoNT-A treatment. Most patients were satisfied with their treatment over several cycles and the data support the effectiveness of BoNT-A for focal spasticity regardless of etiology. Lay Summary While there is a lot of high-quality evidence supporting the efficacy (how well a medication works) and safety of botulinum toxin-A in treating spasticity, most of the research has been done in stroke survivors and there is a need to understand how botulinum toxin-A is used in people living with spasticity due to other causes. In this paper, a group of rehabilitation specialists from Italy describe a study where they reviewed the medical records of all patients who had received repeated botulinum toxin-A treatment for spasticity over a period of 10 years. They found that the two most common causes of the spasticity they treated were stroke and multiple sclerosis (MS). The authors made a number of important observations. Firstly, the doses of botulinum toxin used were typically on the lower end of the recommended dosing range in spasticity. Secondly, the way that stroke survivors and patients with MS are treated with botulinum toxin (e.g., the muscles injected) are different. Nevertheless, most patients said they were overall satisfied with repeated treatment and the findings support the use of botulinum toxin in managing spasticity in patients with a variety of conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMultiple SclerosisMuscle SpasticityNeuromuscular AgentsStrokeAdultAgedFemaleHumansMaleMiddle AgedItalyRetrospective Studies

Stichwörter der Autor:innen

botulinum toxin amultiple sclerosisobservational studyrehabilitationspasticitystroketherapeutics

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • U.O.C. of Neurophysiology, A.O.R.N. A. Cardarelli, Naples, Italy.
  • Neurology Unit, San' Paolo Hospital, Naples, Italy.
  • Neurology Unit, Sant' Andrea University Hospital, Rome, Italy.
  • Ipsen, Milan, Italy.
  • Ipsen, Boulogne-Billancourt, France.

ORCID-Profile: Trinchillo Assunta, Massimo Filippi, Ubaldo Del Carro

Förderung

  • Ipsen

Zitieren

APA

Butera, C., Esposito, M., Assunta, T., Giovannelli, M., Rivaroli, A., Pata, M., Beneteau, M., Filippi, M., Caglioni, P. M., & Del Carro, U. (2025). Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, ‘Real-world’, Multicenter Study. NeuroRehabilitation. https://doi.org/10.1177/10538135251329322

Vancouver

Butera C, Esposito M, Assunta T, Giovannelli M, Rivaroli A, Pata M, et al. Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, ‘Real-world’, Multicenter Study. NeuroRehabilitation. 2025. doi:10.1177/10538135251329322

BibTeX
@article{Butera2025,
  author = {Butera, Calogera and Esposito, Marcello and Assunta, Trinchillo and Giovannelli, Morena and Rivaroli, Anna and Pata, Mario and Beneteau, Mathieu and Filippi, Massimo and Caglioni, Patrizia M and Del Carro, Ubaldo},
  title = {Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, ‘Real-world’, Multicenter Study},
  journal = {NeuroRehabilitation},
  year = {2025},
  doi = {10.1177/10538135251329322}
}
Kostenlos starten →